Health · 51 views
Investigational EGFR x HER3 therapy supports Phase III dose after lung cancer trial
An investigational EGFR x HER3 antibody-drug conjugate demonstrated promising efficacy with a tolerable safety profile in patients with previously treated EGFR-mutated non-small cell lung cancer (NSCLC), supporting selection of the 2.5…
AI Summary
An investigational EGFR × HER3 antibody‑drug conjugate showed promising efficacy and a tolerable safety profile in patients with previously treated EGFR‑mutated non‑small cell lung cancer. The data support selecting a 2.5 mg/kg dose for the global Phase III IZABRIGHT‑Lung01 registrational study. Findings will be presented at the IASLC 2026 World Conference on Lung Cancer in Seoul, Republic of Korea.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedCoverage Context
More from Health
Continue reading recent Health coverage
- The invisible global health workforce: Why nurses matter more than everContinue reading
- AI measurements of heart scans more strongly linked to patient survival than clinician measurementsContinue reading
- Novel Therapy Lands Speedy Approval for Wart-Like Airway DiseaseContinue reading
- Study Strengthens Case for Stent-Free PCI in De Novo Coronary LesionsContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow